Prime Medicine inks $110M upfront BMS collaboration, refocuses pipeline, cash runway to H1 2026

Prime Medicine, Inc.

Received $55M upfront + $55M equity investment ($5.00/share) from BMS for exclusive license to Prime Editing for ex vivo T-cell therapies.
Up to >$3.5B in milestones ($1.4B development, >$2.1B commercialization) plus tiered royalties; BMS locked up shares until Sep 2027.
Pipeline focus: Phase 1/2 CGD data expected in 2025; Wilson's Disease IND/CTA planned for H1 2026.
X-linked CGD program added using PASSIGE technology; cystic fibrosis work continues with CFF funding.
Cost savings plus BMS upfront extend cash runway into first half of 2026 (previously not guided beyond 2025).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.